MBRX
Moleculin Biotech, Inc.
stockNASDAQ
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. the other portfolio targets the metabolism of tumors.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.30 | 2026-11-03 | +4.58% | -0.431 |
| 1M | 0.44 | 2026-10-09 | +1863.80% | 29.892 |
| 3M | 0.43 | 2026-08-10 | +1916.73% | 16.489 |
| 6M | 2.44 | 2026-05-11 | +255.74% | 7.616 |
| 1Y | 12.08 | 2025-11-10 | -28.12% | 4.325 |
| 2Y | 62.75 | 2024-11-11 | -86.17% | — |
| 5Y | 926.25 | 2021-11-10 | -99.06% | 1.302 |
Moleculin Biotech, Inc. (NASDAQ:MBRX) stock price today is $8.68, and today's volume is 7,485. MBRX is up 0.231% today. The 30 day average volume is 277,345. MBRX market cap is $8.85M with 1.02M shares outstanding.